Key catalysts targeted for 2019/2020
Boehringer Ingelheim acquired AOC3 inhibitor to report clinical proof of concept
Phase 2a NASH study in 114 patients for 3 months -last patient last visit complete.Phase 2a clinical trial result and commercial assessment to progress to Phase 2b due from BI -Q4 2019
Phase 2a diabetic retinopathy study in 100 patients for 3 months ->50% recruited Clinical and commercial assessment due from BI -mid 2020
LOXL2 anti fibrotic program
Partnering process to conclude -H2 2019
Mannitol Business (Aridol & Bronchitol) to turn profitable in 2020
US -FDA to complete review H1 2020; if approved -launch milestone US$10m
Sales growth in existing and new territories expected to continue
do not advertise external links.au/upload/CKEditor/untitled%20folder%201/triple2.jpg
PXS=MC $75 M --2 Marketed Products --MEGA Milestones IMMINENT =Disallowed or Buyout Gem, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $42.58M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.3¢ | 3.3¢ | $6.417K | 194.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 106747 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 228097 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| SNT (ASX) Chart |